Mailbox 39, Toronto, Ontario, Canada, M5G1X5
NICE recommends GLP-1 therapy for type 2 diabetes (NG28) when: HbA1c remains elevated despite dual therapy with metformin and another oral agent The patient has a BMI of 35 kg/m or higher (or lower thresholds for certain ethnic groups) Significant weight loss would benefit other obesity-related comorbidities Insulin therapy poses specific risks or is declined by the patient For weight management, NICE has approved specific GLP-1 receptor agonists through Technology Appraisals
If youve ever felt like food has become a battle, know this : youre not alone, and there is a gentler way forward.
Preventive and treatment measures:Regular monitoring of blood pressure: During the use of GLP-1 , patients should regularly monitor blood pressure changes, promptly detect blood pressure abnormalities, and take corresponding measures.Adjusting the dosage of antihypertensive drugs: For patients with pre-existing hypertension, it may be necessary to adjust the dosage of antihypertensive drugs in a timely manner under the guidance of a doctor based on blood pressure monitoring results when using GLP-1 drug
